目的：观察和分析化疗间期联合序贯应用厄洛替尼治疗晚期非小细胞肺癌（NSCLC）的疗效。方法选取晚期NSCLC 患者45例作为研究对象，对于初治患者应用吉西他滨联合铂类进行化疗，对于复治患者应用多西他赛或培美曲塞进行化疗，在化疗间期应用厄洛替尼进行序贯治疗。对患者的近期疗效和毒副反应进行评价和比较。结果初治患者和复治患者的临床有效率分别为27．6％和18．8％，初治患者和复治患者的各项近期疗效结果及临床有效率的差异均无显著性（P ＞0．05），而初治患者的临床控制率显著高于复治患者（P ＜0．05）；具有吸烟史患者的临床有效率显著低于无吸烟史的患者（P＜0．05），年龄≥65岁的初治患者的临床有效率显著高于年龄＜65的初治患者（P ＜0．05），Ⅲb 期的初治患者的临床有效率显著高于Ⅳ期的初治患者（P ＜0．05），病理类型为腺癌的复治患者的临床有效率显著高于病理类型为非腺癌的复治患者（P ＜0．05）；患者的主要副反应为皮疹、恶心、腹泻、呕吐、食欲减退等方面。结论化疗间期联合序贯应用厄洛替尼治疗晚期NSCLC 的临床有效率并不高，吸烟史、年龄、肿瘤分期、病理类型都可能对其疗效产生影响，这种疗法在控制初治患者病情进展方面的效果较显著，且副反应较轻，患者的可耐受度较高。%Objective To observe and analyze the curative effects of the combined sequential application of erlotinib between the chemotherapy periods in the treatment of the patients with ad-vanced non small cell lung cancer (NSCLC).Methods 45 patients with advanced NSCLC were se-lected as the research objects.The patients of the initial treatment were treated with gemcitabine combined with platinum for chemotherapy and the patients of retreatment were treated with doc-etaxel or pemetrexed for chemotherapy.Between the chemotherapy periods,the sequential erlotinib therapy was applied to all the patients.The short-term curative effects and the adverse reactions were evaluated and compared.Results The clinical efficiency of the initial treatment patients and the retreatment patients were 27.6% and 18.8% respectively.There were no significant differences of short-term curative effects and the clinical efficiency between the initial treatment patients and the retreatment patients (P >0.05),while the clinical control rate of the initial treatment patients was significantly higher than that of the retreatment patients (P <0.05).The clinical efficiency of the patients with a smoking history was significantly lower than that of the patients without smok-ing history(P <0.05).The clinical efficiency of the initial treatment patients with age of 65 years or older was significantly higher than that of the initial treatment patients of age < 6 5 years (P <0.05).The clinical efficiency of the initial treatment patients with stage Ⅲb was signifi-cantly higher than that of the initial treatment patients with stage Ⅳ(P <0.05).The clinical ef-ficiency of the retreatment patients with adenocarcinoma pathological type was significantly higher than that of the patients without adenocarcinoma pathological type (P <0.05).The main adverse reactions of the patients were nausea,diarrhea,rash,vomiting,loss of appetite.Conclusion The clinical efficiency of the combined sequential application of erlotinib between the chemothera-py periods in the treatment of the patients with advanced NSCLC is not high.Smoking history, age,tumor stage,pathological type may affect its curative effect.The effects of this therapy in controlling the disease progress of the initial treatment patients are more significant,the adverse reactions are mild,and the tolerance of the patients for the therapy is higher.
展开▼
